Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sygnis Pharma has completed patient enrollment in a double-blind, randomized AXIS 2 Study to evaluate AX200 (G-CSF).
Subscribe to our email newsletter
The study aims to investigate the efficacy and safety of AX200 as a treatment for acute ischemic stroke.
The company anticipates to release initial findings of the AXIS 2 Study this year.
Following the completion of a subsequent three month observation period for the last patient recruited, the data collection will be finalized by the company
Sygnis expects to commence an additional clinical trial to confirm the efficacy of the drug in treating acute stroke patients.
Sygnis chief medical officer Frank Rathgeb said with the completion of patient enrollment they have reached the next milestone of the clinical development of AX200 for the treatment of acute stroke.
"After the completion of a three month monitoring period of this last patient, we will enter the crucial evaluation phase during which we will analyse all collected data and, as a result, gain clarity on the potential of AX200 for the treatment of acute stroke," Rathgeb said.